These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. A locked nucleic acid antisense oligonucleotide (LNA) silences PCSK9 and enhances LDLR expression in vitro and in vivo. Gupta N; Fisker N; Asselin MC; Lindholm M; Rosenbohm C; Ørum H; Elmén J; Seidah NG; Straarup EM PLoS One; 2010 May; 5(5):e10682. PubMed ID: 20498851 [TBL] [Abstract][Full Text] [Related]
7. Evaluation of the effect of 2'-O-methyl, fluoro hexitol, bicyclo and Morpholino nucleic acid modifications on potency of GalNAc conjugated antisense oligonucleotides in mice. Prakash TP; Yu J; Kinberger GA; Low A; Jackson M; Rigo F; Swayze EE; Seth PP Bioorg Med Chem Lett; 2018 Dec; 28(23-24):3774-3779. PubMed ID: 30342955 [TBL] [Abstract][Full Text] [Related]
8. On the in vitro and in vivo properties of four locked nucleic acid nucleotides incorporated into an anti-H-Ras antisense oligonucleotide. Fluiter K; Frieden M; Vreijling J; Rosenbohm C; De Wissel MB; Christensen SM; Koch T; Ørum H; Baas F Chembiochem; 2005 Jun; 6(6):1104-9. PubMed ID: 15861430 [TBL] [Abstract][Full Text] [Related]
9. Effect of 2'-O-[2-[2-(N,N-dimethylamino)ethoxy]ethyl] modification on activity of gapmer antisense oligonucleotides containing 2',4'-constrained 2'-O-ethyl nucleic acid. Pandey SK; Nowak A; Perkins J; Ferng A; Prakash TP Bioorg Med Chem Lett; 2015 Apr; 25(8):1688-1691. PubMed ID: 25804718 [TBL] [Abstract][Full Text] [Related]
13. Down-regulation of VEGF mRNA expression by 2'-O,4'-C-ethylene-bridged nucleic acid (ENA) antisense oligonucleotides and investigation of non-target gene expression. Morita K; Yamate K; Kurakata S; Abe K; Imanishi T; Koizumi M Nucleic Acids Res Suppl; 2002; (2):99-100. PubMed ID: 12903124 [TBL] [Abstract][Full Text] [Related]
14. Drug discovery and development scheme for liver-targeting bridged nucleic acid antisense oligonucleotides. Wada F; Yamamoto T; Kobayashi T; Tachibana K; Ito KR; Hamasaki M; Kayaba Y; Terada C; Yamayoshi A; Obika S; Harada-Shiba M Mol Ther Nucleic Acids; 2021 Dec; 26():957-969. PubMed ID: 34760338 [TBL] [Abstract][Full Text] [Related]
15. Filling the gap in LNA antisense oligo gapmers: the effects of unlocked nucleic acid (UNA) and 4'-C-hydroxymethyl-DNA modifications on RNase H recruitment and efficacy of an LNA gapmer. Fluiter K; Mook OR; Vreijling J; Langkjaer N; Højland T; Wengel J; Baas F Mol Biosyst; 2009 Aug; 5(8):838-43. PubMed ID: 19603119 [TBL] [Abstract][Full Text] [Related]
16. Comparison of hepatic transcription profiles of locked ribonucleic acid antisense oligonucleotides: evidence of distinct pathways contributing to non-target mediated toxicity in mice. Kakiuchi-Kiyota S; Koza-Taylor PH; Mantena SR; Nelms LF; Enayetallah AE; Hollingshead BD; Burdick AD; Reed LA; Warneke JA; Whiteley LO; Ryan AM; Mathialagan N Toxicol Sci; 2014 Mar; 138(1):234-48. PubMed ID: 24336348 [TBL] [Abstract][Full Text] [Related]
17. Novel strategy of liver cancer treatment with modified antisense oligonucleotides targeting human vasohibin-2. Horie S; Suzuki Y; Yamamoto T; Obika S; Mohri K; Kiyota C; Ren Q; Warashina S; Wada Y; Watanabe Y; Mukai H; Sato Y Cancer Sci; 2023 Sep; 114(9):3740-3749. PubMed ID: 37430466 [TBL] [Abstract][Full Text] [Related]